Key Highlights

  • Loss per share was USD 1.29 against an estimated USD 0.90 loss, and the company reported no revenue.
  • Net loss narrowed to USD 6.8 million from USD 8.6 million, and nine-month net loss fell to USD 31.5 million.
  • Cash and cash equivalents were USD 8.7 million, and the filing includes a Going Concern note.
  • A Delaware court validated the July 2025 Reverse Stock Split on November 2, 2026, resolving the petition.

NextCure (NASDAQ:NXTC), a clinical-stage biopharmaceutical company, reported a third quarter 2026 loss of USD 1.29 per share against an estimated loss of USD 0.90. The company reported no revenue, in line with the estimate. Net loss was USD 6.8 million against USD 8.6 million a year earlier, and USD 31.5 million for the nine months against USD 46.4 million.

Research and development expense decreased USD 1.6 million in the quarter and USD 19.3 million for the nine months, while general and administrative expense increased USD 1.6 million in the quarter and USD 0.6 million for the nine months.

Cash and Going Concern Note

Cash and cash equivalents were USD 8.7 million at September 30, 2026, and the accumulated Deficit was approximately USD 468 million. Net cash used in Operating Activities was USD 42.0 million for the nine months. The filing states that expected negative operating cash flows and the need for additional funding raise substantial doubt about the company's ability to continue as a going concern within one year of issuance.

During the nine months, the company sold 99,446 shares under its Wainwright at-the-market agreement for net proceeds of about USD 1.2 million.

Program Transition

On October 6, 2026, the company completed the transfer of the IND and related regulatory responsibilities for LNCB74 to LigaChem under the Transition and Continuation Agreement between the parties. The filing's Liquidity discussion refers readers to its note on liquidity and the going concern assessment for more detail. The filing states LigaChem became the sponsor of the program and assumed responsibility for future development activities and associated costs, and that the company retains rights to potential future development proceeds.

Legal Disclosure and Items to Follow

The filing describes a petition the company filed on September 14, 2026 in the Delaware Court of Chancery under Section 205 of the Delaware General Corporation Law, seeking validation of the certificate of amendment, filed with the Delaware Secretary of State on July 10, 2025, that effected its one-for-twelve reverse stock split and of shares issued in reliance on it. The matter is captioned In re NextCure, Inc., C.A. No. 2026-1203-JTL. On November 2, 2026, the court entered a final order validating the amendment and the shares. The filing states the matter has been resolved, no Liability was recorded and it had no material impact on results. The matter is reported as stated and flagged for human legal review.

The items to follow are financing, cash use, the LigaChem program, the pace of research spending and the company's strategic direction.